Hyperthermic isolation-perfusion with melphalan, a preliminary appraisal of local and general effects in malignant melanoma.
Ten hyperthermic isolation-perfusions with melphalan were performed for invasive malignant malenoma of the limbs. Four cases at stage II and with in transit metastases (up to 15 cm in diameter) had a complete regression. However, no improvement of survival was noticed: 4 out of 5 stage II patients who died, within 1 year after perfusion, developed a generalized disease. Systemic chemotherapy was administered in 3 patients after perfusion, but they died from distant metastases. The need for an adequate adjuvant treatment added to isolation perfusion is discussed.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000097:blood; D010478:Chemotherapy, Cancer, Regional Perfusion; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008545:Melanoma / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010100:Oxygen / Q000097:blood; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D002245:Carbon Dioxide; D008558:Melphalan; D010100:Oxygen